X-Linked Retinitis Pigmentosa (xlrp) Clinical Trials
2 recruiting trials for X-Linked Retinitis Pigmentosa (xlrp). Eligibility criteria explained in plain English.
TrialFinderData lists 2 X-Linked Retinitis Pigmentosa (xlrp) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 / Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by University of Göttingen (1), Frontera Therapeutics (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is FT-002 (genetic, 1 trial).
Track X-Linked Retinitis Pigmentosa (xlrp) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
InsightRP2 Registry
InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease...
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for X-Linked Retinitis Pigmentosa (xlrp), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for X-Linked Retinitis Pigmentosa (xlrp), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for X-Linked Retinitis Pigmentosa (xlrp), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.